Authorized expanded access for ANKTIVA to treat lymphopenia, a life-threatening immune deficiency induced by chemotherapy, radiotherapy, and immunotherapy with depletion of natural killer (NK) and CD4+ CD8+ T cells (lymphocytes)
Expanded Access includes all patients with solid tumors who have failed first-line treatment on chemotherapy, radiotherapy or immunotherapy and exhibit low Absolute Lymphocyte Counts (ALC <1,000/μL)
Presentation at ASCO Annual Meeting 2025 of lymphopenia treatment in patients with 3rd to 6th line metastatic pancreatic cancer significantly prolongs overall survival
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.